Fuji Pharma gains rights to darbepoetin alfa biosimilar in Japan

Home/Pharma News | Posted 12/02/2016 post-comment0 Post your comment

Japan-based Fuji Pharma announced on 5 January 2016 that it had signed a license agreement with Chong Kun Dang Pharmaceutical (CKD Pharma). Under the agreement, Fuji Pharma has the exclusive rights in Japan for the development, manufacture, distribution and sale of CKD Pharma’s darbepoetin alfa biosimilar (CKD‑11101).

Business Aquisition V13F07

Darbepoetin alfa is a synthetic form of erythropoietin. It stimulates erythropoiesis (increases red blood cell levels) and is used to treat anaemia. The drug is effective for improving renal anaemia seen in patients with non-dialysis chronic kidney disease and in haemodialysis patients and is widely used in Japan.

A darbepoetin alfa biosimilar from Kyowa Hakko Kirin was approved in Japan in 2013 [1].

CKD Pharma is still developing its darbepoetin alfa biosimilar. The company has already completed a phase I pharmacokinetics study of CKD-11101 compared to the originator Nesp (darbepoetin alfa) after SC and IV administration in healthy male volunteers. The results of the study showed that CKD-11101 had a comparable pharmacokinetic, pharmacodynamic and tolerability profile to that of Nesp and there were no issues of adverse events after administration of CKD-11101 [2].

This will be Fuji Pharma’s second biosimilar. The company’s Filgrastim BS injection, a recombinant human granulocyte colony-stimulating factor (G-CSF), was approved in November 2012. Filgrastim BS was developed with partner Mochida Pharmaceuticals and was the first biosimilar G-CSF in Japan [3].

Related articles
Biosimilars of darbepoetin alfa 

Japanese firms developing biosimilars

References
1.  GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Japan [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Feb 12]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Japan  
2.  GaBI Online - Generics and Biosimilars Initiative. Phase I study shows darbepoetin alfa biosimilar to be well tolerated [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Feb 12]. Available from: www.gabionline.net/Biosimilars/Research/Phase-I-study-shows-darbepoetin-alfa-biosimilar-to-be-well-tolerated  
3.  GaBI Online - Generics and Biosimilars Initiative. Approval of first biosimilar G-CSF in Japan [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Feb 12]. Available from: www.gabionline.net/Biosimilars/News/Approval-of-first-biosimilar-G-CSF-in-Japan  

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.

Source: Fuji Pharma

comment icon Comments (0)
Post your comment
Related content
Swiss Social Democrat’s for nationalization of Sandoz
28 MD002360
Home/Pharma News Posted 19/11/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010